ResearcherMount Sinai HospitalNo recent work listed

Erin Diane Kennedy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0707-5294; OpenAlex author ID A5078621310. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper

Papers 1

Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Last author DOI 10.1002/cam4.2705 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wei Fang Dai · 1 shared paper, 2020 · strength 0.09
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705 ↗
James Biagi · 1 shared paper, 2020 · strength 0.09
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705 ↗
Kelvin Chan · 1 shared paper, 2020 · strength 0.09
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705 ↗
Nicole Mittmann · 1 shared paper, 2020 · strength 0.09
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705 ↗
Natalie G. Coburn · 1 shared paper, 2020 · strength 0.09
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.